当前位置: 首页 > 期刊 > 《《大家健康》》 > 2008年第5期
编号:11732673
注射用重组葡激酶疗效安全性综述
http://www.100md.com 2008年5月1日 《大家健康》 2008年第5期
     【摘要】葡激酶是由金黄色葡萄球菌分泌的一种胞外酶,具有溶血栓的特性,重组葡激酶系采用基因工程的方法,将克隆的葡激酶基因在大肠杆菌中实现高表达。其作用机理为重组葡激酶与血浆中纤溶酶原形成复合物后,激活纤溶系统,促使纤溶酶原转化为纤溶酶,从而降解纤维蛋白。因重组葡激酶具有纤维蛋白的特异性,所以溶栓效果更强。经临床试验研究表明:注射用重组葡激酶是一种有效、安全的静脉溶栓剂。

    【关键词】注射用重组葡激酶(r-SAK);血栓溶解;疗效;安全性

    Tonghua Yujin Stock Pharmaceutical Co. Limited Jilin Tonghua BaiYan 134001

    【Abstract】staphylokinase is a exoenzyme which secreted by staphylococcus aureus,having the characteristic of thromblysis.Recombinant staphlokinase (r-Sak) were produced by Escherichia coli.which had been cloned the gene of staphylococcus aureus birthing staphylokinase by genetic engineering technology and obtaining high expression. With more powerful effective against thrombus, r-Sak have a specific property on fibrin; its mechanism of action is that r-Sak combines with serum plasminogen to form complex ,activating plasminogen systems and promoting plasminogen turn into plasmin,thereby making fibrin degradation. Clinical study shows injection r-Sak is a high effective and safe iv thromblysis medicines. ......

您现在查看是摘要页,全文长 4808 字符